ArticleCase reports in oncology

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

Bruno Chauffert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.